
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc. is strategically advancing its position in the oncology sector, highlighted by the recent operational expansions of its CNSide Diagnostics, which include securing new laboratory licenses in California, Rhode Island, and Maryland. The company has also received a significant $18 million grant from the Cancer Prevention and Research Institute of Texas, bolstering its research initiatives and reinforcing its commitment to develop therapies for leptomeningeal metastases. Furthermore, ongoing improvements in operational capacity and the potential for enhanced national payor coverage could lead to increased test volumes and early revenue generation from the CNSide CSF assay as Plus Therapeutics progresses through key milestones in drug development.
Bears say
Plus Therapeutics Inc faces significant risks that could negatively impact its stock performance, primarily stemming from the potential failure of its product candidates, including rhenium (186Re) obisbemeda, to show safety and efficacy in clinical trials. Additionally, the company may encounter obstacles in obtaining regulatory approval for its therapies, as well as challenges related to securing suitable reimbursement and facing competition within the pharmaceutical market. The influence of changing macroeconomic factors further compounds these risks, creating an uncertain financial outlook for the company.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares